论文部分内容阅读
生化制药行业是我国医药工业中的一支正在蓬勃发展、不断壮大的新军、它从肉类联合加工工业综合利用发展起来,经历了从粗加工到精加工,从加工原料到制剂生产,从采用传统生化技术到运用现代生化技术几个阶段,在生产管理、质量监督、科学技术、人才培养等方面逐步形成相对独立的体系,已成为我国三大制药行业之一。 目前,全国生化制药企业有250多家,其中70％以上在商业系统,职工约3万人。生产300多种生化药品,其中胰岛素、人工牛黄、催产素、肝素、细胞色素C、尿激酶、胰酶、抑肽酶等都是临床上不可缺少的品种,并出口创汇。1995年工业总产值达29.1亿元,比上年增长33.2％,出口创汇5 000多万美元。 但是,由于我国生化制药起步晚、基础差、投入少,还落后于化学合成制药和传统制药工业,与国外先进水平相比还有较大差距。存在的问题主要有产品老化、低水平重复现象严重;基础薄弱,设备落后;厂小,点多,形不成规模优势;管理体制不顺。这些不利因素对生化制药行业发展的制约应引起各方面充分重视。
The biochemical pharmaceutical industry is a booming and growing new army in the pharmaceutical industry in China. It is developed from the comprehensive utilization of the meat processing industry and has undergone rough processing to fine processing, from processing of raw materials to production of pharmaceutical preparations. From the traditional biochemical technology to the use of modern biochemical technology in several stages, gradually forming a relatively independent system in production management, quality supervision, science and technology, personnel training, etc., has become one of China’s three major pharmaceutical industries. At present, there are more than 250 biochemical pharmaceutical companies in the country, of which more than 70% are in commercial systems and employ about 30,000 people. Produce more than 300 kinds of biochemical drugs, including insulin, artificial bezoar, oxytocin, heparin, cytochrome C, urokinase, trypsin, aprotinin, etc. are all clinically indispensable species, and export foreign exchange. In 1995, the total industrial output value reached 2.91 billion yuan, an increase of 33.2% over the previous year, and the export earned more than 50 million U.S. dollars. However, due to the late start of China’s biochemical pharmaceutical industry, poor foundation, and low investment, it still lags behind chemical synthetic pharmaceuticals and traditional pharmaceutical industries, and there is still a big gap compared with the advanced level in foreign countries. The main problems are aging of products, serious low level of repetition, weak foundation, and backward equipment; small factories, many spots, lack of scale advantages, and unfavorable management systems. These unfavorable factors should give full attention to the restrictions on the development of the biochemical pharmaceutical industry.